Blood-based biomarkers (BBBs) could play a pivotal role in addressing the growing global prevalence of Alzheimer’s disease (AD), offering a promising method for diagnosis, disease monitoring, and treatment effectiveness. Current clinically validated tests help in diagnosing the disease, tracking its progression, evaluating treatment efficacy, and determining patient eligibility for clinical trials.
Evolution of Alzheimer’s Disease Diagnosis
Historically, Alzheimer’s disease has been diagnosed through clinical observations and symptoms, supplemented by more invasive methods like lumbar puncture for cerebrospinal fluid (CSF) analysis or PET imaging scans, available primarily to those with sufficient access and resources.
The emergence of blood-based biomarkers presents a potential shift in AD diagnosis. As clinical development of these tests progresses and their accuracy improves, they could become a vital tool in the global fight against this common form of dementia. However, challenges remain, both in the development of these tests and in their broader clinical application.
Test Equipment and Methodological Challenges
The most accurate blood tests for Alzheimer’s utilize mass spectrometry, which outperforms immune-based methods in terms of reliability and precision. Researchers at Hanyang University College of Medicine in Seoul have conducted an extensive review of current methodologies for measuring Amyloid-beta (Aβ) in plasma. They found significant variability in the diagnostic accuracy of plasma Aβ, with ionization-mass spectroscopy showing superior results compared to other methods like the single molecule array (SIMOA) technology.
Despite the accuracy of mass spectrometry, the technology comes with limitations, including the need for specialized expertise, expensive equipment, and infrastructure not available in many hospitals or clinics. These tests are also time-consuming and have lower throughput compared to immunoassays, which are faster and less expensive. Although immunoassays used for CSF analysis offer automated processing and rapid results, they tend to have lower accuracy and are prone to batch-to-batch variations. However, their lower cost and established presence in laboratories make them a viable option for developing blood biomarker tests.
The Need for Standardization
One of the most significant obstacles in the widespread adoption of blood biomarker tests is standardization. In regions with limited laboratory infrastructure, the ability to collect and process viable samples, such as dried blood spots, could help address these challenges.
The Global Biomarker Standardization Consortium, overseen by the Alzheimer’s Association, is addressing the need for consistent and reproducible results across different tests and manufacturers. According to Prof. Michel Schöll from the University of Gothenburg, true standardization requires establishing and validating cutoff points that can be applied consistently across various methodologies.
Furthermore, the context of the test’s use—whether it is designed to rule in or rule out AD—affects the diagnostic performance and the need for different specificity and sensitivity levels. This adds complexity to creating universally accepted reference values for blood biomarkers.
Ethnic, Medical, and Socioeconomic Diversity
A major gap in current blood biomarker research is the limited representation of diverse populations. Most clinical trials focus on non-Hispanic Caucasian populations in developed countries, overlooking significant ethnic, genetic, and socioeconomic diversity. Co-morbidities such as chronic kidney disease, hypertension, diabetes, and the effects of certain medications can impact biomarker concentrations in the blood, making the need for diverse research even more critical.
Research into how BBBs behave across various ethnic groups, including populations in Africa, South Asia, and Latin America, remains sparse. Yet, it is estimated that around 60% of individuals living with dementia come from low- and middle-income countries, where research on BBBs is underdeveloped. This lack of research could contribute to misdiagnoses and inappropriate treatments.
As noted by Dr. Harald Hampel, Chief Medical Officer at Eisai, and his colleagues, while BBB tests show promise in highly controlled populations, there is an urgent need for studies in more diverse, real-world groups. These studies are essential for establishing reliable reference intervals and cutoffs that perform consistently across all demographics.
Conclusion: The Road Ahead for Alzheimer’s Blood Biomarkers
While blood-based biomarker tests are improving the accuracy of Alzheimer’s diagnosis and facilitating research by selecting appropriate clinical trial cohorts, challenges remain. The successful global implementation of these tests will depend on overcoming issues related to test methodology, standardization, and diverse population representation. With continued research and development, BBB testing holds significant potential to help curb the growing Alzheimer’s epidemic, though widespread adoption may take years to achieve.
Related Topics
